Figure 1.
Study flow diagram.
Table 1.
Characteristics of studies included in primary analysis.
Table 2.
Risk ratio of fatal adverse events by subgroup.
Figure 2.
Risk ratio of fatal adverse events in cancer participants treatment with bevacizumab compare with control.
Table 3.
Fatal adverse events by specific type.